Premium
Iron as a potential co‐factor in the pathogenesis of Kaposi's sarcoma?
Author(s) -
Simonart Thierry,
Noel JeanChristophe,
Andrei Graciela,
Parent Dominique,
Van Vooren JeanPaul,
Hermans Philippe,
LunardiYskandar Yanto,
Lambert Charlie,
Dieye Tandakha,
Farber ClaireMichèle,
Liesnard Corinne,
Snoeck Robert,
Heenen Michel,
Boelaert Johan R.
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19981209)78:6<720::aid-ijc9>3.0.co;2-f
Subject(s) - deferiprone , deferoxamine , pathogenesis , ferric , basic fibroblast growth factor , chemistry , cell growth , cell , in vitro , chelation , cancer research , growth factor , biochemistry , biology , immunology , inorganic chemistry , receptor
The role of iron in the pathogenesis of several tumours is being increasingly investigated. In particular, its involvement in the pathogenesis of Kaposi's sarcoma (KS) is suggested by the distribution of the endemic form of KS corresponding to continental rifts and associated iron‐oxide‐rich volcanic clays. We investigated in vitro to what extent iron supplementation or withdrawal could affect the growth of KS‐derived cells, by analysing the effects of adding iron salts (iron chloride and ferric nitrilotriacetate) and/or reducing iron by iron chelators (desferrioxamine) on KS‐derived cell cultures. The addition of iron salts strongly stimulated the growth of KS cells, as reflected by increase in thymidine incorporation and cell number. Conversely, desferrioxamine and deferiprone inhibited cell growth. The inhibitory effect of iron chelation was more pronounced on rapidly dividing basic fibroblast‐growth‐factor‐stimulated cells. These results may point to a novel therapeutic approach to KS. Int. J. Cancer 78:720–726, 1998. © 1998 Wiley‐Liss, Inc.